A Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c01616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Samsher Singh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore 636921, Singapore. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Quinazolines, Pyrazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Potts Memorial Foundation, National Research Foundation Singapore.
Abstract (Originalsprache)
The Mycobacterium tuberculosis cytochrome bcc:aa3 (cyt-bcc:aa3) oxidase is a validated drug target for tuberculosis treatment. In addition to telacebec (Q203), a clinical-stage drug candidate, several preclinical cyt-bcc:aa3 inhibitors have been reported. However, the bactericidal potency of cyt-bcc:aa3 inhibitors is limited by cytochrome bd oxidase (cyt-bd), an alternative terminal oxidase. We developed a high-throughput whole-mycobacteria assay to identify new cyt-bd inhibitors. Screening 115,398 small molecules identified several new chemical series, including a pyrazolo-quinazoline amine series. Chemical optimization yielded the potent derivative ETX1975-3, which, in combination with Q203, is bactericidal against M. tuberculosis, retains activity against a panel of M/XDR M. tuberculosis clinical isolates, and also shows efficacy against nontuberculous mycobacteria (NTM). Mode of action studies validated the cyt-bd target as the molecular target. While further chemical optimization is required, favorable microbiological, ADMET, and in vivo potency of ETX1975-3 makes it a promising preclinical candidate for tuberculosis and NTM infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore 636921, Singapore.
- Experimental Drug Development Centre, Agency for Science, Technology and Research, Singapore 138670, Singapore.
- School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, United States.
- Antimicrobial Resistance Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology Centre, Singapore 138602, Singapore.
- Department of Chemistry and Biochemistry, Montana State University, 103 Chemistry and Biochemistry, Bozeman, Montana 59717, United States.
ORCID-Profile: Pearly Shuyi Ng, Vikneswaran Mathiyazakan, Garrett Moraski, Marvin Miller, Gerhard Grüber, Kevin Pethe
Förderung
- NIAID NIH HHS
- Potts Memorial Foundation
- National Research Foundation Singapore
- National Institutes of Health
Zitieren
APA
Singh, S., Ng, P. S., Lakshmanan, U., Mathiyazakan, V., Wiggins, T., Lee, B. S., Ang, S. H., Lin Sim, S. W., Santos, M. D., Moraski, G., Miller, M., Berney, M., Grüber, G., & Pethe, K. (2026). A Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01616
Vancouver
Singh S, Ng PS, Lakshmanan U, Mathiyazakan V, Wiggins T, Lee BS, et al. A Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c01616
BibTeX
@article{Singh2026,
author = {Singh, Samsher and Ng, Pearly Shuyi and Lakshmanan, Umayal and Mathiyazakan, Vikneswaran and Wiggins, Thomas and Lee, Bei Shi and Ang, Shi Hua and Lin Sim, Sandra Wei and Santos, May Delos and Moraski, Garrett and Miller, Marvin and Berney, Michael and Grüber, Gerhard and Pethe, Kevin},
title = {A Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c01616}
}
EUVIMED